≥18 years and ≤75 years of age at time of informed consent
Participants with histologically and/or cytologically confirmed relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma
With at least one of evaluable/measurable target lesions per Lugano 2014 criteria
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
Life expectancy of ≥3 months
Sufficient organ function
You may not be if
Central nervous system lymphoma
Previously undergone allogeneic hematopoietic stem cell transplantation or other organ transplants
Any other prior malignancy active within the previous 5 years, except for skin basal cell cancer that has been cured, or carcinoma in situ of the cervix
History of active autoimmune diseases
History of interstitial lung disease, tuberculosis, or other diseases that affect pulmonary function in the past or currently
Uncontrolled disease, including but not limited to uncontrolled diabetes, hypertension, active infections, active peptic ulcers, thromboembolic disease requiring anticoagulation, etc.
Severe cardiovascular diseases
History of severe allergies to protein-based drugs or any component of the study drug
